<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00390091</url>
  </required_header>
  <id_info>
    <org_study_id>LJP 394-90-16</org_study_id>
    <nct_id>NCT00390091</nct_id>
  </id_info>
  <brief_title>Study of LJP 394 (Abetimus Sodium) in Lupus Patients</brief_title>
  <official_title>A Randomized, Double-Blind Study to Evaluate the Safety, Pharmacokinetic and Pharmacodynamic Effects of Abetimus Sodium in Patients With Systemic Lupus Erythematosus (SLE)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>La Jolla Pharmaceutical Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>La Jolla Pharmaceutical Company</source>
  <brief_summary>
    <textblock>
      The primary purpose of this study is to assess the safety and pharmacodynamic effect of LJP
      394 at doses of 100 mg, 300 mg and 900 mg on anti-dsDNA antibody levels in patients with SLE.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      STUDY NOW INCORPORATED INTO PHASE 3 STUDY NCT00089804.
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <start_date>September 2006</start_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>Single</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The assessment of the safety and pharmacodynamic effect of abetimus sodium at</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>doses of 100mg, 300mg, and 900mg in reducing the anti-dsDNA antibody levels in</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>patients with SLE will be based on laboratory data from the central laboratory</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>and confirmed by supporting data. The pharmacodynamic effic will be assessed</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>using historical placebo effect as a control.</measure>
  </primary_outcome>
  <enrollment type="Actual">0</enrollment>
  <condition>Systemic Lupus Erythematosus</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>abetimus sodium (LJP 394)</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Males or females between 12 and 70 years old.

          -  Diagnosis of Systemic Lupus Erythematosus (SLE)

          -  Females must be non-pregnant and non-lactating. Females must agree to use adequate
             birth control methods during the course of the study.

          -  Ability to have weekly intravenous (IV) administration of study drug.

        Exclusion Criteria:

          -  Prior exposure to abetimus sodium within 6 months prior to screening.

          -  Patients not on stable medications for 30 days prior to screening.

          -  Patients with acute or chronic infections.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Matthew D Linnik, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>La Jolla Pharmaceutical Company</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Wallace Rheumatic Study Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90048</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altoona Center for Clinical Research</name>
      <address>
        <city>Duncansville</city>
        <state>Pennsylvania</state>
        <zip>16635</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.ljpc.com</url>
    <description>Sponsor's website</description>
  </link>
  <link>
    <url>http://clinicaltrials.gov/ct/show/NCT00089804?order=1</url>
    <description>STUDY NOW INCORPORATED INTO PHASE 3 STUDY NCT00089804</description>
  </link>
  <verification_date>February 2007</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 17, 2006</study_first_submitted>
  <study_first_submitted_qc>October 17, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 19, 2006</study_first_posted>
  <last_update_submitted>August 31, 2015</last_update_submitted>
  <last_update_submitted_qc>August 31, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 1, 2015</last_update_posted>
  <keyword>Lupus</keyword>
  <keyword>Nephritis</keyword>
  <keyword>Kidney</keyword>
  <keyword>SLE</keyword>
  <keyword>Systemic Lupus Erythematosus</keyword>
  <keyword>Nephritis, Lupus</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lupus Erythematosus, Systemic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

